These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 11922268)

  • 1. Proliferative signaling and disease progression in heart failure.
    Katz AM
    Circ J; 2002 Mar; 66(3):225-31. PubMed ID: 11922268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses.
    Katz AM
    J Cell Mol Med; 2003; 7(1):1-10. PubMed ID: 12767256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology of heart failure: identifying targets for pharmacotherapy.
    Katz AM
    Med Clin North Am; 2003 Mar; 87(2):303-16. PubMed ID: 12693727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maladaptive growth in the failing heart: the cardiomyopathy of overload.
    Katz AM
    Cardiovasc Drugs Ther; 2002 May; 16(3):245-9. PubMed ID: 12374903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cellular and physiologic effects of beta blockers in heart failure.
    Sabbah HN
    Clin Cardiol; 1999 Oct; 22 Suppl 5():V16-20. PubMed ID: 10526699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations.
    Francis GS
    J Cardiovasc Pharmacol; 1998; 32 Suppl 1():S16-21. PubMed ID: 9731691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction.
    Poulsen SH
    Dan Med Bull; 2001 Nov; 48(4):199-210. PubMed ID: 11767125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets.
    Tham YK; Bernardo BC; Ooi JY; Weeks KL; McMullen JR
    Arch Toxicol; 2015 Sep; 89(9):1401-38. PubMed ID: 25708889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoring function in failing hearts: the effects of beta blockers.
    Eichhorn EJ
    Am J Med; 1998 Feb; 104(2):163-9. PubMed ID: 9528736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of chronic heart failure.
    Francis GS
    Am J Med; 2001 May; 110 Suppl 7A():37S-46S. PubMed ID: 11334774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.
    Wang X; Ye Y; Gong H; Wu J; Yuan J; Wang S; Yin P; Ding Z; Kang L; Jiang Q; Zhang W; Li Y; Ge J; Zou Y
    J Mol Cell Cardiol; 2016 Aug; 97():180-90. PubMed ID: 27210827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiocirculatory dynamics in the normal and failing heart.
    Zelis R; Flaim SF; Liedtke AJ; Nellis SH
    Annu Rev Physiol; 1981; 43():455-76. PubMed ID: 6452090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic rationale for the use of beta-blockers in the treatment of heart failure.
    Sabbah HN
    Heart Fail Rev; 2004 Apr; 9(2):91-7. PubMed ID: 15516856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs for left ventricular remodeling in heart failure.
    Frigerio M; Roubina E
    Am J Cardiol; 2005 Dec; 96(12A):10L-18L. PubMed ID: 16399088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart failure, ventricular remodelling and the renin-angiotensin system: insights from recently completed clinical trials.
    Young JB
    Eur Heart J; 1993 Jul; 14 Suppl C():14-7. PubMed ID: 8365422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
    Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
    Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical management of mild-to-moderate heart failure before the advent of beta blockers.
    Abraham WT; Wagoner LE
    Am J Med; 2001 May; 110 Suppl 7A():47S-62S. PubMed ID: 11334776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction.
    Beckwith C; Munger MA
    Ann Pharmacother; 1993 Jun; 27(6):755-66. PubMed ID: 8329800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological therapeutics based on molecular mechanisms].
    Akazawa H; Komuro I
    Nihon Rinsho; 2006 May; 64(5):897-903. PubMed ID: 16689371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.